USFDA issues 7 observations for Natco Pharma's Hyderabad plant after Nov inspection
Synopsis
Key Takeaways
Natco Pharma on Saturday, 21 November 2026, disclosed that the US Food and Drug Administration (USFDA) has issued seven observations following an inspection of its manufacturing facility at Kothur, Hyderabad. The company said it views the observations as procedural and does not anticipate major compliance concerns.
Inspection Details
The USFDA conducted its inspection of the Kothur facility between 12 November and 20 November, according to a regulatory filing by the company. At the conclusion of the inspection, the regulator issued a Form 483 containing the seven observations.
A Form 483 is issued under USFDA procedures when investigators identify conditions that, in their judgement, may constitute potential violations of regulatory requirements and warrant management's attention. The company did not disclose further details of the specific observations.
Company's Response
Natco Pharma expressed confidence in its ability to resolve the flagged issues. 'The company believes that the observations are procedural in nature and is confident of addressing these observations comprehensively within stipulated timelines,' the company stated in its regulatory filing.
Notably, the company's assertion that the observations carry no major compliance risk will be closely watched by investors, given that Form 483 notices — while not automatically resulting in import alerts or warning letters — can escalate if management responses are deemed inadequate by the regulator.
Financial Performance Under Pressure
The USFDA development comes against a backdrop of weakening financials. In Q2 FY27, Natco Pharma's net profit declined 60.8 per cent year-on-year to ₹203 crore, compared to ₹518 crore in Q2 FY26. Revenue from operations also fell 29 per cent to ₹967 crore, from ₹1,363 crore in the corresponding quarter of the previous year.
At the operating level, earnings before interest, taxes, depreciation and amortisation (EBITDA) dropped 55.4 per cent from ₹579 crore a year earlier, underscoring the breadth of the company's earnings compression.
Stock Performance
Shares of Natco Pharma on Friday closed 0.55 per cent lower at ₹817 per share on the Bombay Stock Exchange (BSE). The stock has recorded a 52-week high of ₹1,216.29 and a 52-week low of ₹774. According to exchange data, the stock has declined approximately 40 per cent over the last two years.
What to Watch
The company's formal response to the USFDA's Form 483 observations will be a key near-term trigger. Any escalation — such as a warning letter or import alert — could weigh further on the stock and disrupt US market supplies. Industry analysts will also track whether the ongoing revenue decline stabilises in the coming quarters.